HIV-Selectest is a serodiagnostic enzyme immunoassay (EIA), containing p6 and gp41 peptides, designed to differentiate between vaccine-induced antibodies and true infections. A rapid test version of the HIV-Selectest was developed. Both assays detected HIV antibodies in men and women within 2 to 4 weeks of infection, with sensitivity similar to third-generation EIAs.
Most of the current HIV vaccine candidates contain multiple viral components. As a result, many vaccine recipients react positively in commercial diagnostic assays that detect HIV antibodies, including enzyme immunoassays (EIAs), Western blots (WB), and rapid tests. We have identified conserved sequences in Env gp41 and Gag p6 which are not included in most HIV vaccine candidates. A new HIV EIA termed HIVSelectest was developed, which distinguishes between vaccineinduced antibodies and seroconversion due to true HIV infections (4, 5) .
Before this assay can be implemented as part of the HIV detection algorithm during HIV vaccine trials, it was important to compare its sensitivity to those of currently available thirdgeneration EIAs and rapid tests. In addition, attention must be given to detection of infections in women versus those in men, since women may experience HIV/AIDS differently from men (8, 10) . We have recently developed a rapid test version of the HIV-Selectest in order to facilitate point-of-care testing during vaccine trials.
In the current studies, we evaluated serial samples obtained from the following multiple cohorts of men and women from the United States and Africa: plasma donors who acquired HIV-1 in the United States (Center for HIV/AIDS Vaccine Immunology [CHAVI]; clade B, predominantly males) (9); high-risk subjects identified with having acute HIV-1 infections at U.S. sites participating in the Acute Infection and Early Disease Research Program (AIEDRP; clade B, predominantly males); acutely infected subjects indentified in Africa by the Center for the AIDS Programme of Research in South Africa (CAPRISA; clade C infections, mainly women) (2); subjects participating in the Zambia-Emory HIV Research Project (ZEHRP; clade C discordant couple transmission pairs) (3, 6) ; early (3 to 6 months) postinfection time points in men enrolled in the U.S. Multicenter AIDS Cohort Study (MACS) (7); and women participating in the Women's Interagency HIV Study (WIHS) (11) .
In collaboration with CHAVI, 87 plasma donor seroconversion panels were evaluated. In these panels, blood draws were very frequent (every 3 to 5 days), the date of initial PCRconfirmed infection was available, and viral loads were provided. The HIV-Selectest was performed as described in detail in references 4 and 5. Of the 87 CHAVI panels tested, only 45 reached seroconversion (38 males and 7 females) and could be used for comparison of antibody assay sensitivity. As seen in Fig. 1A , concordant results from the Abbott third-generation test and the HIV-Selectest EIA were seen in 18/45 panels (zero difference in detection day for panels 8 to 25). The Abbott EIA yielded positive results prior to the HIVSelectest in 20/45 panels (positive columns for panels 26 to 45). Surprisingly, the HIV-Selectest EIA scored positive prior to the Abbott test in 7/45 panels (negative columns for panels 1 to 7). On average, the HIV-Selectest EIA detected anti-HIV antibodies 1.6 days (median ϭ 0) after the commercial third-generation Abbott EIA.
It was important to expand our survey to include community clinic settings. Additional panels of confirmed early HIV infections in men and women with predominantly clade B infections were evaluated through collaboration with the AIEDRP, MACS, and WIHS. The HIV-Selectest EIA sensitivity ranged from 98.7 to 100% and from 93.8 to 98.3% in men and women, respectively, based on detection of the first seropositive specimen defined by reference assays in these studies (Fig. 1B) .
Detection of clade C infections was evaluated in the CAPRISA acute infection and ZEHRP discordant couple panels from South Africa and Zambia, respectively. The CAPRISA project was established in South Africa in order to capture early heterosexual clade C infections and to establish the rate of viremia and disease progression. Most of the CA-PRISA participants are women. HIV-1 diagnosis was based on several rapid tests and EIAs and supplemented by PCR-based viral load measurements, and acutely infected subjects were enrolled into a longitudinal follow-up protocol with weekly specimen collection. Samples tested with the HIV-Selectest EIA were the first specimens available after confirmed seroconversion by the serodiagnostic tests used in the CAPRISA study (i.e., within 1 to 4 weeks of estimated infection date). Overall, the HIV-Selectest scored positive no later than 1 sample after seroconversion in 46 panels.
Performance of the HIV-Selectest in capturing clade C in- fections was also evaluated in the ZEHRP discordant couple study. Early seroconversions from 9 female-to-male and 20 male-to-female transmissions were tested. The HIV-Selectest EIA scored positive with the first HIV infection-confirmed bleed from 9/9 males and 19/20 females in this panel (Fig. 1B) . Together, the data obtained in the current studies demonstrated that in spite of the fact that HIV-Selectest EIA is composed of a limited number of peptides from only two HIV-1 proteins (gp41 and p6), its sensitivity to detect early anti-HIV-1 IgG antibodies does not differ significantly from commercially available rapid tests and third-generation EIAs used in the HIV screening algorithms in many countries. Over- all assay sensitivity was found to be 99.1% and 98.1% in early infection samples obtained from males and females, respectively (Fig. 1B) . A two-tailed, unequal sample size, equal variance t test was performed on the combined HIV-Selectest reactivity for the HIV-1-positive males and females. Detection rates were not significantly different between the HIV-infected men and women, irrespective of the infecting HIV-1 viral strains (P value ϭ 0.68). Point-of-care rapid testing is potentially of great value to resource-poor countries. During vaccine trials, a rapid test could help to capture breakthrough infections, which often occur between the 3-month scheduled clinic visits. To that end, we have adapted the HIV-Selectest to a lateral flow test based on immunochromatographic strip (ICS) technology. As seen in Fig. 2A, (Fig. 2A) .
In order to compare the sensitivity of the HIV-Selectest rapid test and EIA with the performance of a third-generation EIA, we evaluated seroconversion panels from SeraCare BioServices, Inc. In the case of panel PRB 917 (Fig. 2B) , the Abbott HIV-1/2-O test was reactive on day 28, while the HIVSelectest EIA and rapid assay (both p6 and gp41) scored positive as early as day 14, with the bands becoming stronger on subsequent days (Fig. 2B) .
In several proof-of-concept studies conducted with the HIVSelectest rapid test, assay specificity is around 99.4% based on 76 seronegative healthy individuals and 81 samples obtained from HIV-uninfected vaccine trial participants (Fig. 2C, top) . Assay sensitivity is currently in the range of 99.2 to 100% for confirmed infections with HIV-1 clade B, C, and E viruses (Fig.  2C, bottom) , but individual samples may give different patterns of intensity with the peptide bands, in agreement with what was found in the EIA version of the HIV-Selectest (4).
The addition of the HIV-Selectest (EIA and rapid test) to the detection algorithm during ongoing vaccine trials could facilitate early diagnosis of breakthrough infections and reduce the number of questionable HIV-seropositive samples that need nucleic acid testing. 
